An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Trial Profile

An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Emricasan (Primary)
  • Indications Liver cirrhosis; Portal hypertension
  • Focus Therapeutic Use
  • Sponsors Conatus Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Feb 2016 According to a Conatus Pharmaceuticals media release, the US FDA has granted Fast Track designation to the company's emricasan development program for the treatment of liver cirrhosis caused by nonalcoholic steatohepatitis (NASH), based on data from this trial.
    • 14 Nov 2015 Results will be presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), according to a Conatus Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top